



Trends in mRNA Vaccine Development and Applications

Guest Editor:

Prof. Dr. Janos Szebeni

Nanomedicine Research and Education Center, Institute of Translational Medicine, Semmelweis University, 1089 Budapest, Hungary

Deadline for manuscript submissions:

30 September 2024

Message from the Guest Editor

Since the roll-out of mRNA-lipid nanoparticle (LNP)-based COVID-19 vaccines in 2020, billions of people have been immunized with this type of vaccine, representing a novel technology platform to fight infectious diseases. Pfizer-BioNTech's Comirnaty and Moderna's Spikevax, the lead mRNA-LNP formulations, trigger immune responses that effectively reduce the pathogenicity of SARS-CoV-2, saving millions from severe illness or death. The mechanism of this benefit, details of these vaccines' structure and function, as well as their side effects have been the subjects of unprecedented scientific and public attention, yet novelties in these fields emerge each day. Many believe that technology will surpass all other approaches of gene and pharmacotherapy, but there is also a lot of scientific and public discussion of presently ill-understood adverse effects, of which clarification is necessary to secure safe beside efficacy.

The goal of this Special Issue of Pharmaceutics is to provide a 2024 update on the most recent developments and prospects in this field. Original research data and comprehensive reviews are all welcome to be submitted to this Special Issue.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma